What is the 13F Pro Quality Score for BTAI?

13F Pro ranks BioXcel Therapeutics, Inc. (BTAI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BTAI's current score at https://13fpro.ai/research/BTAI (free sign-up required for the full ranking).

Where does 13F Pro source BTAI data?

All BioXcel Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. BioXcel Therapeutics, Inc. files with the SEC under CIK 1720893. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BTAI in?

BioXcel Therapeutics, Inc. (BTAI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BTAI research updated on 13F Pro?

BTAI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BioXcel Therapeutics, Inc.(BTAI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1720893 BTAI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BTAI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BioXcel Therapeutics, Inc. (BTAI), a Healthcare sector company. BTAI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), BioXcel Therapeutics, Inc. reports quarterly revenue of $206.0K, net income of $-12.7M, free cash flow of $-11.8M. Top institutional holders of BTAI by reported 13-F value include MILLENNIUM MANAGEMENT, ARMISTICE CAPITAL,, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. BTAI trades on the Nasdaq exchange and files with the SEC under CIK 1720893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioXcel Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$206.0K

Net Income

Q1 2026

$-12.7M

Free Cash Flow

Q1 2026

$-11.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-71.7% YoY

$642.0KFY 2025

FY22 $375.0KFY23 $1.4MFY24 $2.3MFY25 $642.0K

Net Income

-17.3% YoY

$-69.9MFY 2025

FY22 $-165.8MFY23 $-179.1MFY24 $-59.6MFY25 $-69.9M

Operating Income

+25.0% YoY

$-50.5MFY 2025

FY22 $-159.6MFY23 $-171.8MFY24 $-67.2MFY25 $-50.5M

EPS (Diluted)

+26.9% YoY

$-5.73FY 2025

FY22 $-0.11FY23 $-1.82FY24 $-7.84FY25 $-5.73

Total Assets

+17.2% YoY

$44.9MFY 2025

FY22 $205.9MFY23 $73.7MFY24 $38.3MFY25 $44.9M

Total Debt

+31.2% YoY

$134.5MFY 2025

FY22 $93.1MFY23 $100.6MFY24 $102.5MFY25 $134.5M

Op. Cash Flow

+20.0% YoY

$-57.6MFY 2025

FY22 $-135.3MFY23 $-155.0MFY24 $-72.0MFY25 $-57.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$642.0K -71.7%	$2.3M +64.2%	$1.4M +268.0%	$375.0K	—	—
Net Income	$-69.9M -17.3%	$-59.6M +66.7%	$-179.1M -8.0%	$-165.8M -55.0%	$-106.9M -30.1%	$-82.2M
Operating Income	$-50.5M +25.0%	$-67.2M +60.9%	$-171.8M -7.6%	$-159.6M -49.3%	$-106.9M -29.9%	$-82.3M
EPS (Diluted)	$-5.73 +26.9%	$-7.84 -330.4%	$-1.82 -1561.4%	$-0.11 -46.1%	$-0.07 -6.8%	$-0.07
Total Assets	$44.9M +17.2%	$38.3M -48.0%	$73.7M -64.2%	$205.9M -14.0%	$239.4M +8.9%	$219.9M
Total Debt	$134.5M +31.2%	$102.5M +1.9%	$100.6M +8.1%	$93.1M	—	—
Operating Cash Flow	$-57.6M +20.0%	$-72.0M +53.5%	$-155.0M -14.5%	$-135.3M -64.7%	$-82.2M -23.8%	$-66.3M

AI Insight: BTAI Financial Trends

BTAI is a pre-revenue biotech burning cash with mounting debt and persistently negative equity, showing no clear path to clinical or commercial traction.

• Revenue remains at $0M across all eight quarters through Q1 2026; no commercial progress detected.

• Operating cash burn improved from $-23M in Q2 2024 to $-12M in Q1 2026, but remains structurally negative.

• Total debt climbed from $103M (Q2 2024) to $123M (Q1 2026); equity remains deeply negative at $-106M.

⚠ Net losses spiked to $-31M in Q3 2025, the worst quarter on record, though improved to $-13M by Q1 2026.

⚠ Negative equity deteriorated to $-106M in Q1 2026; company is technically insolvent on a book-value basis.

AI Insight: BTAI Ratio Trends

Insufficient financial data to establish meaningful trends; only two ROA figures available across nine quarters.

• ROA deteriorated from -50.7% in Q2 2024 to -75.2% in Q1 2025, reflecting persistent unprofitability.

⚠ Data sparse: OpMargin, NPM, ROE, ROIC, and D/E missing across all periods; unable to assess profitability trajectory or leverage.

Get alerted when BTAI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BioXcel Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BTAI

MILLENNIUM MANAGEMENT LLC
$2.6M1,936,760 sh
ARMISTICE CAPITAL, LLC
$2.6M1,910,076 sh
OAKTREE CAPITAL MANAGEMENT LP
$323.2K241,188 sh
GEODE CAPITAL MANAGEMENT, LLC
$308.7K230,168 sh
VANGUARD CAPITAL MANAGEMENT LLC
$277.8K207,339 sh
JONES FINANCIAL COMPANIES LLLP
$166.1K131,789 sh
Man Group plc
$129.3K96,473 sh
STATE STREET CORP
$123.4K92,118 sh
FMR LLC
$121.0K90,300 sh
VANGUARD FIDUCIARY TRUST CO
$113.8K84,921 sh

Fund	Value	Shares
MILLENNIUM MANAGEMENT LLC	$2.6M	1,936,760
ARMISTICE CAPITAL, LLC	$2.6M	1,910,076
OAKTREE CAPITAL MANAGEMENT LP	$323.2K	241,188
GEODE CAPITAL MANAGEMENT, LLC	$308.7K	230,168
VANGUARD CAPITAL MANAGEMENT LLC	$277.8K	207,339
JONES FINANCIAL COMPANIES LLLP	$166.1K	131,789
Man Group plc	$129.3K	96,473
STATE STREET CORP	$123.4K	92,118
FMR LLC	$121.0K	90,300
VANGUARD FIDUCIARY TRUST CO	$113.8K	84,921

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BTAI on your watchlist

Track score changes the day BioXcel Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BTAI a good stock to buy?

13F Pro's AI-powered analysis of BioXcel Therapeutics, Inc. (BTAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BTAI are available on the BTAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BTAI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BTAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioXcel Therapeutics, Inc.'s investment landscape.